Related references
Note: Only part of the references are listed.A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens
Prakash Thapaliya et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis
Elias Jabbour et al.
BLOOD (2011)
Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents
Waleed Ghanima et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients
Pierre Morel et al.
BLOOD (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
Constantine S. Tam et al.
BLOOD (2009)
Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Constantine S. Tam et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
Ruben A. Mesa et al.
LEUKEMIA RESEARCH (2009)
Portal hypertension secondary to myelofibrosis with myeloid metaplasia: A study of 13 cases
Mohannad Abu-Hilal et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2009)
Risk factors for leukemic transformation in patients with primary myelofibrosis
Jocelin Huang et al.
CANCER (2008)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Ayalew Tefferi et al.
BLOOD (2006)
Palliative goals, patient selection, and perioperative platelet management - Outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic
Ruben A. Mesa et al.
CANCER (2006)
Splenectomy and chronic thromboembolic pulmonary hypertension
X Jaïs et al.
THORAX (2005)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia
G Barosi et al.
BLOOD (2001)
Palliative splenectomy in myelofibrosis with myeloid metaplasia
RA Mesa et al.
LEUKEMIA & LYMPHOMA (2001)
Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: A retrospective analysis of 26 cases
G Akpek et al.
JOURNAL OF SURGICAL ONCOLOGY (2001)
Share Paper
